Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 9/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830549 | 0.93 | LMNA (0.52) | LMNATP53HDAC8JAK2HDAC6 | |
| SCHEMBL16270244 | 0.86 | FAAH (0.50) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL831386 | 0.86 | JAK2 (0.67) | LMNASMN1; SMN2HDAC8MEN1KMT2A | |
| SCHEMBL4275826 | 0.85 | HDAC1 (0.56) | LMNATSHRHDAC8KMT2AJAK2 | |
| SCHEMBL831684 | 0.83 | HDAC8 (0.60) | NPC1RAB9ASMN1; SMN2HDAC8MEN1 | |
| SCHEMBL12810617 | 0.83 | JAK2 (0.55) | HDAC8JAK2HDAC6FAAHHTT | |
| SCHEMBL15694822 | 0.82 | HDAC8 (0.52) | HDAC8JAK2HDAC6HTT | |
| SCHEMBL13933030 | 0.82 | HDAC8 (0.52) | HDAC8JAK2HDAC6HTT | |
| SCHEMBL832059 | 0.82 | TP53 (0.61) | LMNATP53NPC1TSHRRAB9A | |
| SCHEMBL832133 | 0.81 | HDAC8 (0.65) | NPC1RAB9ASMN1; SMN2HDAC8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | BEZWADA BIOMEDICAL, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | BEZWADA BIOMEDICAL, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-8143325-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1931334-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | Bezwada Biomedical LLC (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030538-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030538-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030464-A2 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | OGFR, LOX, DDO | LMNA 1459/4885TP53 3956/4885NPC1 3093/4885 |
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | HAO2, AOC2, AOC1 | LMNA 3327/4885TP53 4776/4885NPC1 2150/4885 |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | OGFR, LOX, OPRM1 | LMNA 1845/4885TP53 3365/4885NPC1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.